Influence Explorer

• Summary

  overview of the committee's finances

  Total Raised:

  $161,079

  Total Spent:

  $146,906

  Cash on Hand:

  $65,663

  Debts:

  $0

• Top Recipients

  Employee Color Block

  Individuals

  PAC Color Block

  PAC

  Includes contributions from the organization’s employees, their family members, and its political action committee.

• Republicans vs. Democrats

  in dollars. "Other" includes 3rd parties and organizations without official party affiliation.

• State vs. Federal

  in dollars

• Top PAC Recipients

  Employee Color Block

  Individuals

  PAC Color Block

  PAC

  Includes contributions from the organization’s employees, their family members, and its political action committee.

Lobbying On Behalf of Pharmaceutical Rsrch & Mfrs of America

• Names of Lobbyists

  • Stacey Alexander,
  • Jane Alonso,
  • Mike Anway,
  • Dena Battle,
  • Michael Berman,
  • Maya Bermingham,
  • Jordan Bernstein,
  • Erin Book,
  • Dave Boyer,
  • Randy Burkholder,

• Firm Hired	Amount
  Covington & Burling	$364,000
  East End Group	$270,000
  Cauthen, Forbes & Williams	$240,000
  Tiber Creek Health Strategies	$240,000
  Peck, Madigan et al	$240,000
  Elmendorf Ryan	$240,000
  Arnold & Porter	$220,000
  Hart Health Strategies	$200,000
  Bravo Group	$200,000
  BGR Group	$190,000

• Most Frequently Disclosed Lobbying Issues

  • Health Issues,
  • Copyright, Patent & Trademark,
  • Medicare & Medicaid,
  • Pharmacy,
  • Fed Budget & Appropriations,
  • Trade,
  • Medical Research & Clin Labs,
  • Taxes,
  • Economics & Econ Development,
  • Science & Technology

• Most Frequently Disclosed Bills

  Bill No.	Title
  H.R.3590	Service Members Home Ownership Tax Act of 2009

• Recent Lobbying Contracts

  Date	Registrant	Summary
  July 13, 2012	G. Fox Consulting	PDUFA View registration
  June 7, 2012	Desimone Consulting, LLC	Issues related to the impact of the bio-pharmaceutical industry on the economy; access to medicines and other medical therapies; the development of new medical therapies and regulatory matters regarding the bio-pharmaceutical industry; policy changes to Medicare Part B & D; intellectual property protections in foreign trade agreements. View registration

The tables show occurrences of "Pharmaceutical Rsrch & Mfrs of America" in public comments on proposed federal regulations.

• Documents Submitted by the Organization

  • Submissions
  • Agency
  • Docket
  • Date
  • Toggle 1 ITA Request for Public Comments Concerning Regulatory Cooperation between the United States and the European Union that Would Help Eliminate or Reduce Unnecessary Divergences in Regulation and in Standards Used in Regulation that Impede U.S. Exports 2011
  • Toggle 1 CDC Requirements for Importers of Nonhuman Primates 2011
  • Toggle 1 CDC Draft Action Plan – A Public Health Action Plan to Combat Antimicrobial- Resistance 2011
  • Toggle 1 FDA Draft Guidance for Industry on Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies; Availability 2011
  • Toggle 1 HRSA Exclusion of Orphan Drugs for Certain Covered Entities under 340B Program 2011
  • Toggle 1 ITA Request for Public Comments Concerning Regulatory Cooperation Activities that Would Help Eliminate or Reduce Unnecessary Regulatory Divergences in North America that Disrupt U.S. Exports 2011
  • Toggle 1 FDA Draft Guidance for Industry and FDA Staff on Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets; Availability 2011
  • Toggle 1 FDA Periodic Review of Existing Regulations; Retrospective Review Under Executive Order 13563 2011

• Mentions in Document Text

  • Mentions
  • Agency
  • Docket
  • Date
  • Toggle 2 FDA Draft Guidance for Industry on Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies; Availability 2011
  • Toggle 2 FDA Draft Guidance for Industry and FDA Staff on Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets; Availability 2011
  • Toggle 2 HRSA Exclusion of Orphan Drugs for Certain Covered Entities under 340B Program 2011
  • Toggle 1 FDA Draft Guidance for Industry on Medication Guide Distribution Requirements and Inclusion of Medication Guides in Risk Evaluation and Mitigation Strategies (REMS); Availability 2011
  • Toggle 1 ITA Request for Public Comments Concerning Regulatory Cooperation Activities that Would Help Eliminate or Reduce Unnecessary Regulatory Divergences in North America that Disrupt U.S. Exports 2011
  • Toggle 1 CDC Draft Action Plan – A Public Health Action Plan to Combat Antimicrobial- Resistance 2011
  • Toggle 1 CMS Hospital Outpatient Prospective Payment; Ambulatory Surgical Center Payment; Hospital Value-Based Purchasing Program; Physician Self-Referral; and Provider Agreement Regulations on Patient Notification Requirements 2011
  • Toggle 1 FDA Draft Guidance for Industry on Safety Labeling Changes; Implementation of the Federal Food, Drug, and Cosmetic Act; Availability 2011
  • Toggle 1 ITA Request for Public Comments Concerning Regulatory Cooperation between the United States and the European Union that Would Help Eliminate or Reduce Unnecessary Divergences in Regulation and in Standards Used in Regulation that Impede U.S. Exports 2011
  • Toggle 1 FDA 510(k) Implementation: On-line Repository of Medical Device Labeling, including Photographs; Public Meeting 2011

Table shows employees of "Pharmaceutical Rsrch & Mfrs of America" that sat on federal advisory committees.

• Agency
• Representation

• Toggle Department of Commerce 1 person on 1 committee